Strategic partnerships Synaffix has a strong track record of out-licensing its ADC platform with partners including ADC Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio and Kyowa Kirin, indicating high partner demand and potential for expanded collaborations or new licensing deals.

Clinical-stage advantage With a clinically validated platform generating multiple ADCs in development and several in Phase 1 trials, there are clear sales opportunities to expand licensing, co-development, or rapid deployment of Synaffix’s technology to accelerate partners' pipelines.

Acquisition leverage As a Lonza-acquired entity, Synaffix benefits from the backing and reach of a large life sciences group, which can facilitate large-scale commercialization partnerships, global licensing conversations, and integrated services for partners.

Emerging verticals Beyond traditional ADCs, Synaffix is applying its platform to immune cell engagers and targeted gene therapy, presenting cross-sell opportunities into multi-billion-dollar markets and potential uptake by gene editing or cell therapy collaborators.

Recent collaborations Recent licensing and collaboration announcements with Boehringer Ingelheim, Elevation Oncology, Illumina and Sidewinder Therapeutics demonstrate ongoing market validation and open doors for new BD discussions, including multi-target and multi-asset deals.